Shots:

• The P-III 17103 study evaluates the potential for chronic dasiglucagon infusion delivered via a pump to prevent hypoglycemia in neonates up to 12mos. old with CHI. The results of this trial are expected in Q2’22
• The primary objective of the trial is to reduce or eliminate the need for intensive hospital treatment, reduce the frequency of dangerous low blood glucose, need for constant feeding, and to delay or eliminate the need for pancreatectomy
• Dasiglucagon is a glucagon analog that is stable in aqueous solution and is suitable for chronic pump use and received ODD from the US FDA and EC in 2017

 Ref: Globe Newswire | Image: Zealand Pharma